Trials / Not Yet Recruiting
Not Yet RecruitingNCT07052877
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Royal North Shore Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | PSMA PET/CT scan | PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab. |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2025-07-07
- Last updated
- 2025-07-11
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT07052877. Inclusion in this directory is not an endorsement.